Compare RR & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RR | LRMR |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 483.0M | 455.8M |
| IPO Year | 2023 | 2014 |
| Metric | RR | LRMR |
|---|---|---|
| Price | $1.92 | $5.04 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $4.00 | ★ $16.50 |
| AVG Volume (30 Days) | ★ 6.7M | 2.0M |
| Earning Date | 05-13-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,045,000.00 | N/A |
| Revenue This Year | $75.68 | N/A |
| Revenue Next Year | $78.28 | $1,816.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.99 | N/A |
| 52 Week Low | $1.69 | $1.61 |
| 52 Week High | $7.43 | $6.42 |
| Indicator | RR | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 34.57 | 57.68 |
| Support Level | $1.81 | $3.14 |
| Resistance Level | $2.04 | $5.37 |
| Average True Range (ATR) | 0.14 | 0.31 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 11.00 | 87.96 |
Richtech Robotics Inc is a robotics and artificial intelligence (AI) technology company focused on developing embodied AI systems that aims to improve the efficiency and productivity of businesses. The company trains proprietary artificial intelligence models on in-house data to operate robotic systems in the real world. It designs, engineers, manufactures, and deploys next generation embodied AI systems to serve a wide range of industries, including food service, retail, industrial manufacturing, automotive, healthcare, and hospitality. The company's offerings include Commercial Robotic Products, Industrial Robotic Products and Data Services. The company generated the majority of its revenue through product revenue (i.e. outright hardware sales).
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.